Randomized controlled trial.
To study the magnitude of bone loss at forearm in persons with acute spinal cord injury (SCI) & the effect of early administration of Zoledronic acid on its’ prevention.
Sawai Man Singh Medical College, Jaipur, India.
Sixty patients with acute SCI were randomized either to receive standard medical and nursing care or Zoledronic acid infusion in combination with standard medical and nursing care. Areal bone mineral density (aBMD) was measured at the forearm (radius + ulna) once patients were medically stable using Dual Energy X-Ray Absorptiometry (DXA) at baseline and at 3, 6 and 12 months.
Significant differences in aBMD was found between the control & Zoledronic acid group at 1/3 forearm (− 0.064; 95% CI − 0.092 to − 0.036, p = 0.001), mid forearm (− 0.059; 95% CI − 0.084 to − 0.034, p = 0.001), UD forearm (− 0.048; 95% CI − 0.097 to 0.001, p = 0.016) and total forearm (− 0.048; 95% CI − 0.088 to − 0.008, p = 0.021) at 1 year in the paraplegic patients with SCI. Similar significant difference was also observed at 1/3 forearm (− 0.046; 95% CI − 0.073 to − 0.019, p = 0.002), mid forearm (− 0.063; 95% CI − 0.088 to − 0.037, p < 0.0001), UD forearm (− 0.084; 95% CI − 0.101 to − 0.067, p < 0.0001) and total forearm (− 0.115; 95% CI − 0.132 to − 0.097, p < 0.0001) respectively at 1 year in the quadriplegic patients with SCI. Significant differences in aBMD between the groups at 6 months post infusion was also observed at these sites in quadriplegic patients. [1/3 forearm − 0.022; 95% CI − 0.039 to − 0.005; p = 0.015, Mid forearm − 0.023; 95% CI − 0.042 to − 0.004; p = 0.019, UD forearm − 0.041; 95% CI − 0.055 to − 0.027; p < 0.0001 and Total forearm − 0.049; 95%CI − 0.062 to − 0.036; p < 0.0001]. Bone loss was reduced in the Zoledronic acid treated group compared to the standard treatment group in both paraplegic and quadriplegic patients.
Single dose of 5mg intravenous Zoledronic acid is an effective treatment in preventing bone loss at the forearm for 12 months following acute spinal cord injury.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Sheng-Dan, J., Li-Yang, D., & Lei-Sheng, J. (2006). Osteoporosis after spinal cord injury. Osteoporosis International,17, 180–192.
Kiratli, B. J., Smith, A. E., Nauenberg, T., Kallfelz, C. F., & Perkash, I. (2000). Bone mineral and geometric changes through the femur with immobilization due to spinal cord injury. Journal of Rehabilitation Research and Development,37, 225–233.
Sheng-Dan, J., Lei-Sheng, J., & Li-Yang, D. (2006). Mechanisms of osteoporosis in spinal cord injury. Clinical Endocrinology,65, 555–565.
Shapiro, J., Smith, B., Beck, T., Ballard, P., Dapthary, M., BrintzenhofeSzoc, K., et al. (2007). Treatment with Zoledronic acid ameliorates negative geometric changes in the proximal femur following acute spinal cord injury. Calcified Tissue International,80, 316–322.
Slade, J. M., Bickel, C. S., Modlesky, C. M., Majumdar, S., & Dudley, G. A. (2005). Trabecular bone is more deteriorated in spinal cord injured versus estrogen-free postmenopausal women. Osteoporosis International,16, 263–272.
Modlesky, C. M., Majumdar, S., Narasimhan, A., & Dudley, G. A. (2004). Trabecular bone microarchitecture is deteriorated in men with spinal cord injury. Journal of Bone and Mineral Research,19, 48–55.
Bubbear, J. S., Gall, A., Middleton, F. R., Ferguson-Pell, M., Swaminathan, R., & Keen, R. W. (2011). Early treatment with Zoledronic acid prevents bone loss at the hip following acute spinal cord injury. Osteoporosis International,22, 271–279.
Green, J. R., Muller, K., & Jaeggi, K. A. (1994). Preclinical pharmacology of CGP 42′446, a new, potent, heterocyclic bisphosphonate compound. Journal of Bone and Mineral Research,9, 745–751.
Jonathan, R. G., & Michael, J. R. (2002). Pharmacologic profile of Zoledronic acid: a highly potent inhibitor of bone resorption. Drug Development Research,55, 210–224.
Widler, L., Jaeggi, K., Glatt, M., Müller, K., Bachmann, R., Bisping, M., et al. (2002). Highly potent geminal bisphosphonates from pamidronate disodium (Aredia) to Zoledronic acid (Zometa). Journal of Medicinal Chemistry,45(17), 3721–3738.
Frey-Rindova, P., De Bruin, E. D., Stussi, E., Dambacher, M. A., & Dietz, V. (2000). Bone mineral density in upper and lower extremities during 12 months after spinal cord injury measured by peripheral quantitative computed tomography. Spinal Cord,38, 26–32.
Gilchrist, N. L., Frampton, C. M., Acland, R. H., Nicholls, M. G., March, R. L., Maguire, P., et al. (2007). Alendronate prevents bone loss in patients with acute spinal cord injury: A randomized, double-blind, placebo-controlled study. Journal of Clinical Endocrinology and Metabolism,92, 1385–1390.
Schnitzer, T. J., Kim, K., Marks, J., Yeasted, R., Simonian, N., & Chen, D. (2016). Zoledronic acid treatment after acute spinal cord injury: Results of a randomized, placebo controlled pilot trial. PM R,8, 833–843.
Cranney, A., Wells, G., Willan, A., Griffith, L., Zytaruk, N., Robinson, V., et al. (2002). Meta-analyses of therapies for postmenopausal osteoporosis II Meta-analysis of alendronate for the treatment of postmenopausal women. Endocrine Reviews,23, 508–516.
Conflict of interest
The authors do not declare any conflicts of interests.
Ethical standard statement
Institute ethical committee clearnce was taken for the study. Also the study was registered in Clinical Trials Registry-India (CTRI/2018/03/012408).
Written informed consent was taken from all the study participants.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Goenka, S., Sethi, S. Zoledronic Acid Attenuates Early Bone Loss at Forearm in Patients with Acute Spinal Cord Injury. JOIO (2020). https://doi.org/10.1007/s43465-020-00158-8
- Bone loss
- Spinal cord injury (SCI)
- Zoledronic acid
- Dual energy x-ray absorptiometry (DXA)